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Interferon, originally detected by its capacity to  inhibit viral replication in  vitro 
(1), has long been suspected to play a  role in viral infections in vivo (2). Thus, it was 
noted that interferon appeared at the right time and in the right place to limit viral 
growth  (3). Nevertheless, a  simple correlation between the amount  of interferon and 
the severity of a  viral disease seems insufficient to make a  strong case for interferon as 
a  defense  mechanism.  With  the  availability of  potent  anti-interferon  antisera,  it 
became  possible to  demonstrate  more convincingly that  interferon  may  determine 
viral pathogenicity (4-6). 
An interesting illustration for this is influenza virus infection in mice carrying the 
dominant allele Mx. Adult animals with this gene resist the lethal effect of large doses 
of mouse-adapted influenza viruses, titers of virus grown in their organs remain low, 
and  interferon  is  hardly  detectable  (7,  8).  Nevertheless,  injection  of potent  anti- 
interferon antibodies renders Mx-bearing mice as susceptible to lethal influenza virus 
infection as non-Mx-bearing mice  (8). That  interferon has a  protective role in vivo, 
however,  has  so far  not  been  demonstrated  directly. Because  newborn  Mx-bearing 
mice are virtually as susceptible to orthomyxoviruses as their Mx-negative counterparts 
(9), we were able to determine the efficacy of interferon in protecting newborn mice 
differing at the Mx locus. 
Materials  and  Methods 
Mice.  A/J and CBA/J mice were obtained from G. L. Bomholtg~rd, Ry, Denmark. Inbred 
A2G mice, homozygous for the dominant resistance allele Mx  (7)  were bred locally. Timed 
pregnancies of crosses (A2G ×  CBA/J)F1, heterozygous for Mx, and (A/J ×  CBA/J)Fa, devoid 
of Mx, were arranged in our laboratory. 
Interferon Treatment.  Interferon was induced by Newcastle disease virus in mouse C-243 cells 
and was partially purified to  1 ×  10  T reference units per mg protein, as previously described 
(10).  Mock interferon was prepared in the same way except that the interferon inducer was 
omitted. Newborn mice were marked and injected subcutaneously in the interscapular region 
with 0.05 ml of interferon on days 1, 2, and 3 after birth to give the total amounts of reference 
units  per  mouse  indicated  in  the  text.  Marked  controls within  each  litter were  similarly 
inoculated with mock interferon. 
Virus Challenge.  Animals were infected intraperitoneally on day 2 after birth. Lethal doses 
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of the following  viruses were used:  TURH, a hepatotropic influenza A variant, was derived 
from  A/Turkey/England/63  (Havl,  Nav3)  (11). Encephalomyocarditis  virus  (EMC)  was 
passaged in monolayer cultures of L929 cells as described (12). Vesicular stomatitis virus (VSV), 
serotype Indiana, was grown and stored as previously described (12). 
Results and Discussion 
Newborn  mice of crosses  (A/J  ×  CBA/J)F1  and  (A2G  ×  CBA/J)Fa  were  used. 
A/J and CBA/J mice are devoid of Mx, whereas A2G mice are homozygous for Mx. 
Because  A/J  and  A2G  mice  are  related  strains  sharing,  for  example,  the  major 
histocompatibility locus  (13),  there  is  a  considerable overall similarity between  the 
two sets of crosses. Within  each litter, some mice were treated with  interferon,  and 
others were similarly treated with control material (mock interferon). The challenge 
viruses used  were TURH,  to which  adult  Mx-bearing animals  are  highly  resistant 
(11), and EMC and VSV, both of similar virulence for mice bearing Mx or devoid of 
it (14). 
From the  data  in Table I, it  appears that  interferon,  even at  the highest  dosage 
used  (8  ×  105  interferon  U/mouse),  did  not  protect  (A/J  ×  CBA/J)F1  mice from 
death upon challenge with the influenza virus TURH.  This confirms earlier obser- 
vations  on  the  negligible  role  played  by  interferon  in  influenza  virus  infection  of 
ordinary mice (5).  In contrast,  all  (A2G ×  CBA/J)Fa  mice treated with the highest 
dose of interferon survived, and 10 times less interferon protected almost half of them. 
With  100 times less interferon, both Mx and non-Mx bearers died, with the difference 
that death was significantly delayed in presence of Mx (P <  0.001). When no interferon 
was given, Mx bearers died also somewhat later than their non-Mx counterparts, but 
this  was  barely significant.  This  slight  delay  of death  may have  been  due  to  the 
production of traces of interferon in response to infection. Tables II and III show that 
the lethal effects of EMC and VSV were inhibited to a similar extent in both sets of 
mice. 
This host gene-dependent difference of interferon action selective for a  given virus, 
demonstrated here in vivo, mirrors faithfully the features observed in vitro. Isolated 
Mx-bearing cells, such as macrophages (12), liver parenchymal cells (16), or embryo 
fibroblasts  (H.  Arnheiter  and O.  Hailer, unpublished  observations)  are much more 
sensitive  than  non-Mx-bearing  cells  to  protection  by  interferon  against  influenza 
TABLE I 
Protection of Newborn Mice by Interferon against Lethal Intraperitoneal Infection with Influenza  Virus 
TURH* 
(A/J ×  CBA/J)FI (genotypes +/+)  (A2G X CBA/J)F1 (genotype Mx/+)  Significance of 
Interferon  difference in 
U/mouse  Surviving/total  Median survival  Surviving/total  Median survival  survival times 
number infected  time  number infected  time 
d  d  P 
8 ×  105  0/20  3.7  19/19  >42  <0.001 
8 ×  104  0/13  3.4  13/30  8.5  <0.001 
8 X  10  s  0/10  2.9  0/18  4.4  <0.001 
--  0/37  2.5  0/44  3.3  0.03 
* Newborn mice were treated with mouse interferon as described in Materials and Methods, Controls within the same 
litter were inoculated with a mock interferon preparation. Animals were infected intraperitoneally on day 2 after birth 
with  100 LD~o (as titrated in susceptible  adult  mice) of hepatotropic influenza A/TUR/Engl/63 (Havl, Nay3)  (11). 
Deaths were recorded daily, 
:~ Probability P that the observed differences  between Mx bearers and +/+ mice were due to chance was calculated by the 
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TABLE II 
Protection of Newborn Mice by Interferon against Lethal Intraperitoneal Infection with the Picornavirus 
EMC 
(A/J X CBA/J)FI (genotype +/+)  (A2G X CBA/J)F1 (genotype Mx/+)  Significance of 
Interferon  difference in 
U/mouse  Surviving/total  Median survival  Surviving/total  Median survival  survival time~ 
number infected  time  number infected  time 
d  d  P 
8 ×  105  2/5  7.0  4/8  >7.0  >0.05 
8 ×  104  0/13  5.0  0/10  4.1  :>0.02 
--  0/16  2.3  0/11  2.5  >0.05 
* Newborn mice were given mouse interferon as indicated in Materials and Methods. They were infected at day 2 after 
birth with 0.05 ml of virus dilution containing 103 mean tissue culture infective doses (as titrated on Lg~ cells) per mouse 
of EMC (12).  Deaths were recorded daily. 
:~ Probability P as indicated in Table I. 
TABLE III 
Protection of Newborn Mice by Interferon against Lethal Intraperitoneal Infection with the Rhabdovirus 
VSV 
(A/J x  CBA/J)F~ (genotype +/+)  (A2G X CBA/J)FI (genotype Mx/+)  Significance of 
Interferon  difference in 
U/mouse  Surviving/total  Median survival  Surviving/total  Median survival  survival time:~ 
number infected  time  number infected  time 
d  d  P 
8 ×  104  7/14  >9.0  9/14  >9.0  >0.05 
8 x  103  2/20  5.7  3/14  5.5  ::~0.05 
--  0/20  3.3  0/23  3.3  >0.05 
* Newborn  mice were treated with  interferon as  indicated  in  Materials and  Methods.  They were given  0.05  ml of a 
dilution of VSV containing 250 mean tissue culture infective doses (as titrated in ~  cells)  (12) on day 2 after birth. 
Deaths were recorded daily. 
:~ Probability P as indicated in Table I. 
viruses. When unrelated viruses are used, no influence of Mx on the antiviral activity 
of interferon is seen. 
The abrogation of resistance of adult Mx-bearing mice by anti-interferon antibodies 
and  the  enhanced  potency  of  exogenous  interferon  toward  orthomyxoviruses  as 
observed both in Mx-bearing cells and in intact animals, taken together, make up a 
coherent  picture  of the  role  of interferon  in  this  case  of inborn  resistance:  upon 
infection with influenza virus in mature hosts, a  first round of replication  generates 
small amounts of interferon, sufficient  to prevent  viral spread  in Mx  bearers  at  the 
level of potential target cells, whereas the same or even larger amounts of interferon 
eventually formed in mice devoid of Mx only marginally influence the final outcome 
(17).  The susceptibility  of immature Mx bearers may be related  to their inability  to 
make adequate amounts of interferon, rather than to their inability to respond to it. 
The effect of interferon toward other viruses is independent of Mx. How this seemingly 
specific  action  of interferon  is  brought  about  we  do  not  know.  Several  antiviral 
mechanisms seem to be activated in interferon-treated cells (18). It is therefore possible 
that  different  viruses are inhibited  by  different  interferon  mechanisms that  may or 
may not be elicited in a given host cell. Observations by Nilsen et al. (19), for example, 
indicate  that  interferon  induces  a  selective  antiviral  state  in  embryonal  carcinoma 
cells.  It may therefore be appropriate  to postulate a  variety of antiviral  states, each 
affecting the replication pathway of defined groups of viruses and each governed by 
certain host genes. The present data would be compatible with such a  view. 
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the  protective  activity  of interferon  toward  influenza  virus,  the  same  preparation 
judged as showing antiviral  activity in Mx-bearing mice would not exhibit  any such 
activity in mice of a  different genotype. Furthermore,  it is likely that similar interac- 
tions  between  interferon  and  host  genes  are  important  in  the  expression  of non- 
antiviral effects of interferon, such as effects on delayed type hypersensitivity (20) and 
cell proliferation  (21).  It may be that,  in man, host genes affecting interferon  action 
will  also  prove  to  be  important  in  determining  sensitivity  to  viral  infections  and 
response to interferon therapy. 
Summary 
The efficacy of interferon  in antiviral  protection of newborn mice differing at the 
Mx locus was investigated.  Adult mice bearing the allele Mx exhibit  a  high degree of 
specific resistance toward lethal challenge with influenza viruses. In contrast, newborn 
Mx carriers are virtually as susceptible to influenza viruses as newborn mice devoid of 
Mx. Resistance can be abrogated by treating adult animals with anti-interferon serum. 
Here,  we  provide  direct  evidence  of a  virus-specific  effect  of interferon  in  vivo: 
newborn  mice  carrying  the  resistance  gene  Mx  could  be  protected  against  lethal 
influenza  virus  infection  with  doses  of interferon  that  were  not  protective  in  the 
absence of Mx. The efficacy of interferon towards a  picornavirus  (encephalomyocar- 
ditis virus)  and a  rhabdovirus  (vesicular stomatitis virus)  was independent  of Mx. 
We thank Mrs. M. Acklin for technical assistance. 
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